American Journal of Cardiology
Volume 105, Issue 3 , Pages 283-287 , 1 February 2010

Comparison of 80 versus 10 mg of Atorvastatin on Occurrence of Cardiovascular Events After the First Event (from the Treating to New Targets [TNT] Trial)

  • John C. LaRosa, MD

      Affiliations

    • State University of New York, Health Science Center, Brooklyn, New York
    • Corresponding Author InformationCorresponding author: Tel: 718-270-2611; fax: 718-270-4732
    • ,
  • Prakash C. Deedwania, MD

      Affiliations

    • VA Central California Healthcare System and UCSF School of Medicine, Fresno, California
    • ,
  • James Shepherd, MD

      Affiliations

    • University of Glasgow, Glasgow, United Kingdom
    • ,
  • Nanette K. Wenger, MD

      Affiliations

    • Emory University, Atlanta, Georgia
    • ,
  • Heiner Greten, MD

      Affiliations

    • Hanseatic Heart Center, Asklepios Klinik St. Georg, Hamburg, Germany
    • ,
  • David A. DeMicco, PharmD

      Affiliations

    • Pfizer, Inc., New York, New York
    • ,
  • Andrei Breazna, PhD

      Affiliations

    • Pfizer, Inc., New York, New York
    • ,
  • TNT Investigators

Received 9 June 2009 ,Revised 16 September 2009 ,Accepted 16 September 2009.

References 

  1. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  2. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C TNT Steering Committee Members and Investigators. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am J Cardiol. 2004;93:154–158
  3. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. Am Stat J Assoc. 1989;84:1065–1073
  4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–2752
  6. Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O, et al. Total cardiovascular disease burden—comparing intensive with moderate statin therapy: insights from the IDEAL trial. J Am Coll Cardiol. 2009;54:2353–2357
  7. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med. 2007;147:1–9
  8. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes (The Treating to New Targets (TNT) study). Diabetes Care. 2006;29:1220–1226
  9. Deedwania P, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919–928
  10. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005;46:1405–1410
  11. Sever PS, Poulter NR, Dahlof B, Wedel H Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol. 2005;96:39F–44F
  12. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia. 2005;48:2482–2485

 The TNT study was funded by Pfizer, Inc., New York, New York.

PII: S0002-9149(09)02396-0

doi: 10.1016/j.amjcard.2009.09.025

American Journal of Cardiology
Volume 105, Issue 3 , Pages 283-287 , 1 February 2010

Article Tools

* Image Usage & Resolution